Compare Merck & Co., Inc. (MRK) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs State Street Technology Select Sector SPDR ETF — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while State Street Technology Select Sector SPDR ETF trades at $198.78 (market cap $132.55B). The key difference: Merck & Co., Inc. is far larger — about 2.7× State Street Technology Select Sector SPDR ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while State Street Technology Select Sector SPDR ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and State Street Technology Select Sector SPDR ETF for 50 Days on average.
| MRK | XLK | |
|---|---|---|
Market Cap | $351.28B | $132.55B |
Volume | 7,969,665 | 9,063,135 |
Sector | Health | Sector/Thematic |
52-Week High | $156.43 | $202.00 |
52-Week Low | $82.49 | $127.49 |
Typical Hold Time | 98 Days | 50 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
XLK trades at $197.79, down 1.79% on the day, with a bullish technical signal driven by moving averages. The ETF shows neutral oscillators and key support at $196. Recent news highlights concentration risks in its holdings, with some analysts favoring alternative tech ETFs for better diversification. Dividend activity is scheduled for late 2026.
Outlook remains cautiously optimistic given bullish technicals, but concentration in chip stocks poses a risk. Opportunities include AI-driven growth exposure, while risks involve interest rate sensitivity and sector-specific volatility. Investors should weigh diversification against growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
